An Open Label, Expanded Access Program of Dupilumab in Adults With Severe IgE-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab
Latest Information Update: 14 Oct 2024
At a glance
- Drugs Dupilumab (Primary)
- Indications Food hypersensitivity
- Focus Expanded access; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 14 Oct 2024 New trial record